Nanopublications LDF server

Matches in Nanopublications for { ?s ?p "voriconazole for injection is an azole antifungal indicated for the treatment of adults and pediatric patients 2 years of age and older with invasive aspergillosis 1 1 candidemia non neutropenics and other deep tissue candida 1 2 esophageal candidiasis 1 3 serious fungal infections caused by scedosporium apiospermum fusarium fusarium solani 1 4 voriconazole is indicated in adults and pediatric patients 2 years of age and older for the treatment of invasive apergillosis ia in clinical trials the majority of isolates recovered were aspergillus fumigatus there was a small number of cases of culture proven disease due to species of aspergillus other than a fumigatus see clinical studies 14 1 14 5 12 4 voriconazole is indicated in adults and pediatric patients 2 years of age and older for the treatment of candidemia in non neutropenic patients and the following candida infections disseminated infections in skin and infections in abdomen kidney bladder wall and wounds see clinical studies 14 2 14 5 12 4 voriconazole is indicated in adults and pediatric patients 2 years of age and older for the treatment of esophageal candidiasis ec in adults and pediatric patients 2 years of age and older see clinical studies 14 3 14 5 12 4 voriconazole is indicated for the treatment of serious fungal infections caused by scedosporium apiospermum asexual form of pseudallescheria boydii and fusarium spp including fusarium solani in adults and pediatric patients 2 years of age and older intolerant of or refractory to other therapy see clinical studies 14 4 12 4 specimens for fungal culture and other relevant laboratory studies including histopathology should be obtained prior to therapy to isolate and identify causative organism s therapy may be instituted before the results of the cultures and other laboratory studies are known however once these results become available antifungal therapy should be adjusted accordingly" ?g. }

• association label "voriconazole for injection is an azole antifungal indicated for the treatment of adults and pediatric patients 2 years of age and older with invasive aspergillosis 1 1 candidemia non neutropenics and other deep tissue candida 1 2 esophageal candidiasis 1 3 serious fungal infections caused by scedosporium apiospermum fusarium fusarium solani 1 4 voriconazole is indicated in adults and pediatric patients 2 years of age and older for the treatment of invasive apergillosis ia in clinical trials the majority of isolates recovered were aspergillus fumigatus there was a small number of cases of culture proven disease due to species of aspergillus other than a fumigatus see clinical studies 14 1 14 5 12 4 voriconazole is indicated in adults and pediatric patients 2 years of age and older for the treatment of candidemia in non neutropenic patients and the following candida infections disseminated infections in skin and infections in abdomen kidney bladder wall and wounds see clinical studies 14 2 14 5 12 4 voriconazole is indicated in adults and pediatric patients 2 years of age and older for the treatment of esophageal candidiasis ec in adults and pediatric patients 2 years of age and older see clinical studies 14 3 14 5 12 4 voriconazole is indicated for the treatment of serious fungal infections caused by scedosporium apiospermum asexual form of pseudallescheria boydii and fusarium spp including fusarium solani in adults and pediatric patients 2 years of age and older intolerant of or refractory to other therapy see clinical studies 14 4 12 4 specimens for fungal culture and other relevant laboratory studies including histopathology should be obtained prior to therapy to isolate and identify causative organism s therapy may be instituted before the results of the cultures and other laboratory studies are known however once these results become available antifungal therapy should be adjusted accordingly" assertion.